Literature DB >> 2575381

The direct activation of human multidrug resistance gene (MDR1) by anticancer agents.

K Kohno1, S Sato, H Takano, K Matsuo, M Kuwano.   

Abstract

Enhanced expression of a multidrug-resistance gene (MDR1) is observed in some cancer patient, but any regulatory mechanisms of MDR1 gene expression in this phenomenon is not yet known. In this study, the regulation of MDR1 gene was analysed by transient expression assays in the presence of anticancer agents. We found that MDR1 promoter could be activated directly on the addition of anticancer agents including vincristine, daunomycin, adriamycin and colchicine. The results suggest that the level of MDR1 mRNA expression is associated with previous chemotherapy, including drugs that select the multidrug resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2575381     DOI: 10.1016/0006-291x(89)92761-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  42 in total

1.  Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1.

Authors:  Ranajoy Chattopadhyay; Soumita Das; Amit K Maiti; Istvan Boldogh; Jingwu Xie; Tapas K Hazra; Kimitoshi Kohno; Sankar Mitra; Kishor K Bhakat
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

2.  Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter.

Authors:  Y Makino; T Ohga; S Toh; K Koike; K Okumura; M Wada; M Kuwano; K Kohno
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

Review 3.  Targeted vectors for gene therapy of cancer and retroviral infections.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1996-12       Impact factor: 2.695

Review 4.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

Authors:  Eugen Ruckhäberle; Thomas Karn; Lars Hanker; Regine Gätje; Dirk Metzler; Uwe Holtrich; Manfred Kaufmann; Achim Rody
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

Review 6.  Stem cells and tissue-engineered skin.

Authors:  A Charruyer; R Ghadially
Journal:  Skin Pharmacol Physiol       Date:  2009-02-04       Impact factor: 3.479

7.  MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.

Authors:  C Ramachandran; A Sauerteig; K S Sridhar; R J Thurer; A Krishan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.

Authors:  W Walther; U Stein
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

9.  Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.

Authors:  T Abe; T Mori; Y Wakabayashi; M Nakagawa; S P Cole; K Koike; M Kuwano; S Hori
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

10.  Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer.

Authors:  Zhongpeng Zhu; Baocheng Wang; Jingwang Bi; Cong Zhang; Yan Guo; Huili Chu; Xiuju Liang; Chen Zhong; Jun Wang
Journal:  Tumour Biol       Date:  2013-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.